[ALDH1, CD133, CD34-positive cancer stem cells in lung adenocarcinoma in patients who had a new coronavirus infection and retained the persistence of viral proteins in the lung tissue]. / ALDH1-, CD133-, CD34-pozitivnye rakovye stvolovye kletki v adenokartsinome legkogo u patsientov, perenesshikh novuyu koronavirusnuyu infektsiyu SARS-CoV2.

Lung cancer occupies a leading position in the structure of global cancer morbidity and mortality, due to the biological properties of the key pool of tumor cells - cancer stem cells (CSCs). The effects of SARS-CoV2 on tumor CSCs and its niche have not been studied. OBJECTIVE: To study CSCs in lung adenocarcinomas after COVID19. MATERIAL AND METHODS: Surgical material from lung adenocarcinoma from 12 patients who had a new coronavirus infection and from 12 patients who did not have COVID19 was examined. Analysis of clinical and anamnestic data, macroscopic and microscopic examination of tumor samples and adjacent intact tissue, immunohistochemical reactions using antibodies to virus proteins and CSC markers ALDH1, CD133 and CD34 were performed. RESULTS: Adenocarcinoma samples from patients in the main group showed a significant increase in the number of cells expressing the CSCs markers ALDH1, CD133 and CD34 compared to adenocarcinoma samples from control group patients without SARS-CoV2 infection. We found an increase in the number of CSCs in patients with adenocarcinoma metastasis in lymph nodes in both the main and control groups. CSCs of lung adenocarcinomas from SARS-CoV2 survivors contain virus proteins Nucleocapside and Spike protein. CONCLUSIONS: We found an increase in the number of CSCs with expression of ALDH1, CD133 and CD34 in lung adenocarcinoma in patients with new coronavirus infection. Increased number of ALDH1+, CD133+ CD34+ CSCs in tumor tissue enhance the metastatic potential of lung adenocarcinoma. The Nucleocapsid and Spike proteins of SARS-CoV2 virus are detectable in lung tissue from patients with new coronavirus infection, both in adenocarcinoma cells, CSCs, and in type II pneumocytes, macrophages, and endothelial cells, suggesting prolonged persistence of the virus proteins and probably the virus.

[Pulmonary alveolar proteinosis associated with persistence of SARS-CoV2 virus]. / Legochnyi al'veolyarnyi proteinoz, assotsiirovannyi s persistentsiei virusa SARS-CoV2.

Alveolar proteinosis is a rare lung disease characterized by the accumulation of protein-lipid complexes in the alveoli due to impaired surfactant utilization by alveolar macrophages. The frequency is from 2 to 4 cases per 1 million adult population. We present an observation of pulmonary alveolar proteinosis in a patient with a history of coronavirus pneumonia.

[Adenocarcinoma of the lung against the background of usual interstitial pneumonia]. / Adenokartsinoma legkogo na fone obychnoi interstitsial'noi pnevmonii.

Lung adenocarcinoma against the background of idiopathic pulmonary fibrosis according to the world literature ranges from 2.7% to 48%, the incidence increases every year after the diagnosis of idiopathic pulmonary fibrosis. We present a clinical and morphological analysis of an autopsy observation of lung adenocarcinoma that developed against the background of corticosteroid-treated usual interstitial pneumonia in a 78-year-old woman. According to the results of histological and immunohistochemical studies, the diagnosis was formulated as: multicentric non-mucinous invasive adenocarcinoma of the right and left lungs with a lepidic growth pattern with background of usual interstitial pneumonia.

[The proapoptotic factor HLDF in the normal, hyperplastic and neoplastic endometrium].

Antibodies to the factor HLDF are shown to be specific markers of apoptosis and permit the estimation of the rate of programmed cell death in the course of a normal menstrual cycle and in pathologic endometrial processes. HLDF expression in the epitheliocytic cytoplasm makes it possible to evaluate apoptosis at early stages, before the emergence of the first morphological signs and after apoptotic body formation. The study shows increased apoptotic processes at the end of a normal menstrual cycle and during neoplastic cell transformation. Antibodies to the HLDF factor may be used as a new immunohistochemical marker for the differential diagnosis of benign and malignant endometrial processes.